One of the difficulties for preventing the evolution of a tumor is that cancer progression can be promoted by undifferentiated or migrating cells whose states could follow different directions. At the 40th edition of Barcelona Biomed conferences at the Institute for Research in Biomedicine (IRB Barcelona), which took place from Nov. 27 to 29, 2023, and is entitled “Cancer in Context: Cellular, Tissue, and Organismal Determinants of Malignant Fates,” Angela Nieto presented her latest data on epithelial-to-mesenchymal transition (EMT). Read More
MicroRNAs (miRNAs) play an important role in modulating neuronal stress responses, but their impact on neuroprotection has been poorly studied. Multiple sclerosis (MS) is the most common inflammatory disease affecting the central nervous system. Researchers have recently attempted to identify potential miRNAs that play a protective role in neuroinflammation. Read More
Circular RNAs (circRNAs) are involved in the development of several diseases, which makes them promising for investigation. A recent study conducted by Soochow University investigators focused on a circRNA, circTENM3 (hsa_circ_0071478), which is derived from the TENM3 gene and may aid in the diagnosis of prostate cancer, as well as serve a therapeutic target. Read More
Pasithea Therapeutics Corp. has received written responses from the FDA to questions submitted for a type 2 pre-IND meeting regarding the clinical development plan for PAS-004 (CIP-137401). Read More
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized radiolabeled compounds acting as GABA(A) receptor subunit α2β2γ1 (GABRA2) positive allosteric modulators acting as positron-emission tomography (PET) and autoradiography imaging agents reported to be useful for the diagnosis of neurological disorders. Read More
Inmed Pharmaceuticals Inc. has identified a lead cannabinol (CBN) analogue candidate, INM-089, to advance into additional in vivo studies for age-related macular degeneration (AMD). Read More
Aberrant NLRP3 inflammasome activation is at the root of a wide number of conditions, from heart, gastrointestinal, kidney or liver disorders to neuroinflammatory diseases such as Parkinson’s disease or multiple sclerosis. Researchers from Nodthera Ltd. have reported on NT-0796, an NLRP3 inflammasome inhibitor with an in vivo brain penetration profile. Read More
Allianthera (Suzhou) Biopharmaceutical Co. Ltd. has disclosed EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from Shandong Provincial Hospital have published details on the discovery and preclinical characterization of a novel potent microtubule polymerization inhibitor for the treatment of cancer. Read More
CSPC Pharmaceutical Group Ltd.’s SYH-2053 injection has obtained clearance from China’s National Medical Products Administration (NMPA) to enter clinical trials in China. Read More
Cytokinetics Inc. has identified bicyclic piperazinones with the ability to modulate skeletal muscle contractility reported to be useful for the treatment of amyotrophic lateral sclerosis, spinal muscular atrophy, myasthenia gravis, chronic obstructive pulmonary disease, stress urinary incontinence, sarcopenia, obesity and peripheral vascular disease, among others. Read More
KSQ Therapeutics Inc., in collaboration with The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), have announced FDA clearance of an IND application for a phase I/II study of KSQ-001EX, KSQ’s lead engineered tumor-infiltrating lymphocyte (eTIL) program. Read More
University of Dundee has divulged cyclin-dependent kinase 8 (CDK8) and/or CDK19 inhibitors reported to be useful for the treatment of cancer. Read More
LW-231, under development by Shanghai Longwood Biopharmaceuticals Co. Ltd., is a novel bifunctional molecule designed to simultaneously modulate hepatitis B virus (HBV) capsid assembly and activate cGAS-STING pathway. Preclinical data were recently presented. Read More
Cancer Research Technology Ltd. has described inhibitors of nuclear factor κB kinase subunit α (CHUK; IKK-1; IKK-α) reported to be useful for the treatment of inflammation and cancer. Read More
